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Abstract Kashin-Beck Disease (KBD) is an endemic,
chronic and degenerative osteoarthropathy principally
occurring in children. The characteristic pathological
change of KBD is chondrocyte necrosis in hyaline articular
cartilage. Proteoglycans are one of the major components in
the extracellular matrix of articular cartilage, and disrupted
proteoglycan metabolism and loss of proteoglycans in artic-
ular cartilage from KBD patients has been observed. In this
mini-review, we discuss the close relationship between
chondrocyte death including necrosis and loss of proteogly-
can, and its potential mechanism during KBD onset and
development, which may provide new clues for KBD
research.
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Introduction
Kashin-Beck Disease (KBD) is an endemic, chronic and
degenerative osteoarthropathy affecting approximately 3
million people in China [1, 2]. It principally occurs in
childhood [3], with the breakdown of cartilage starting in
children as early as 2 or 3-years-old [1], and results in
growth disturbances [3]. Its main clinical symptoms include
diarthrodal joint deformation and limited joint mobility. In
the most severe cases, decreased limb length and short
stature are also observed due to the focal and irregular
closure of the growth plates [2]. The characteristic patho-
logical change of KBD is chondrocyte necrosis in hyaline
cartilage including articular cartilage and growth plates from
different peripheral joints. Other pathological changes in-
clude cartilage surface fibrillation, chondrocyte cluster for-
mation and more importantly, matrix destruction resulting in
the loss of proteoglycans (PGs) [1, 2]
PGs are one of the major components in the extracellular
matrix (ECM) of articular cartilage. They are remarkably
complex macromolecules consisting of one or several types
of polysaccharide glycosaminoglycan (GAG) side chains
and a unique core protein. Depending upon the nature of
their GAG chains, PGs can be categorised as heparan sulph-
ated PGs (HSPGs), keratan sulphate PGs (KSPGs), chon-
droitin sulphate PGs (CSPGs) and dermatan sulphate PGs
(DSPGs). Alternatively, PGs can also be named according
to their unique core proteins, such as aggrecan [4].
Aggrecan is one of the major PGs distributed in the ECM
of articular cartilage. It contains both CS/DS and KS GAG
side chains attached to an extended core protein. Several
aggrecan monomers can bind to hyaluronan, and this non-
covalent interaction is stabilised through an additional inter-
action with link protein so forming stable ternary com-
plexes, especially in the pericellular and territorial matrix
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around chondrocytes in articular cartilage [5]. Aggrecan
plays an important role in the biomechanical properties of
cartilage and hence contributes to the main function of
cartilage in synovial joints, to withstand compressive load-
ing during movement [5]. The highly negatively charged
GAG chains of aggrecan attract the influx of positive ions
such as Na+ and K+, which increases the osmotic pressure in
the tissue. This contributes to the large water content present
in the ECM of articular cartilage and thereby provides the
biomechanical properties to resist the compressive loading
applied to joints. Therefore, the function of articular carti-
lage is dependent on a high aggrecan concentration being
present in the tissue ECM [6]. In degenerative joint diseases
such as osteoarthritis (OA) and rheumatoid arthritis (RA),
loss of PGs especially aggrecan from articular cartilage is
regarded as the key initial event in disease onset and devel-
opment [7] and is considered as a target for intervention that
would slow the progression of disease. This is followed by
collagen network degradation, which is considered to be an
irreversible event for disease development.
Mechanisms of PG loss in OA and RA have been eluci-
dated and involve increased presence of the inflammatory
cytokines interleukin 1 (IL-1) and tumour necrosis factor
(TNF) that induce chondrocytes and synovial cells to produce
and secrete Matrix MetalloProteinases (MMP) and A
Disintegrin And Metalloproteinase with Thrombospondin
Motifs (ADAMTS) proteinases that are responsible for the
degradation of collagens and PGs, respectively [8]. The path-
ological sites of cleavage within the core protein of aggrecan
by these enzymes is well documented (Fig. 1) and results in
the loss of the GAG rich domains of the core protein from the
tissue. Although the underlying aetiologies between KBD and
the other degenerative joint diseases are different, similar
mechanisms of cartilage degradation, i.e. PG loss and matrix
destruction have been proposed and studied in KBD.
Proteoglycan catabolism in KBD
Evidence for PG catabolism in KBD patients has been
provided from several previous studies in which GAG
depletion has been observed in the articular cartilage
from KBD patients [2, 9], indicating that the loss of
PGs plays a pivotal role during KBD development.
Interestingly, a distinct difference in the loss of PGs
from the different zones of articular cartilage was seen
between juvenile and adult patients [2, 9, 10]. In the
juvenile KBD patients, loss of sulphated GAG (sGAG)
staining in articular cartilage was mainly localised to
areas within the deep zone where chondrocyte necrosis
was observed [2, 9]. However, there was sGAG staining
in the other zones of articular cartilage, suggesting the
association of PG loss with cell death during KBD
onset in children. In contrast, the depletion of sGAG
was observed in the surface and middle zone of articu-
lar cartilage from adult KBD patients, similar to that
seen in osteoarthritic patients [2, 10]. Therefore, it is
now believed that KBD pathology in adults is more like
sub-type of OA with a rare aetiology [11] because their
pathological and metabolic changes in articular cartilage
are quite similar to those observed in OA patients,
although some differences in gene expression profiles
have been recently reported [12].
The mechanism of PG depletion from articular carti-
lage of KBD patients is not clearly understood.
However, studies suggest that increased catabolism of
aggrecan by ADAMTS4 and/or TS5 in articular carti-
lage may be involved as an elevated expression of BC-
13, a neo-epitope generated by aggrecanases through
cleavage of the interglobular domain within the core
protein of aggrecan, has been observed in articular
cartilage from both juvenile and adult KBD patients
[2]. MMPs may also contribute to the aggrecan degra-
dation as increased production of MMP-13, one of the
major members of the MMP family responsible for
pathological changes in degenerative joint diseases, has
been recently reported in the synovial fluid from KBD
patients [13].
Moreover, inflammatory cytokines IL-1 and TNF may be
involved in PG catabolism in KBD patients as elevated
levels of these cytokines have been reported in synovial
fluid and serum from patients diagnosed with KBD [2,
14–17]. It is thought that joint tissues respond to these
increased levels by up-regulating production and secretion
of MMPs and ADAMTS proteinases, eventually leading to
the degradation of PG in articular cartilage.
Fig. 1 Schematic demonstration of aggrecan degradation. The domain
structure of aggrecan core protein with different regions is shown. G1,
2 and 3 are the globular domains, IGD is the interglobular domain, KS,
CS-1 and CS-2 are the glycosaminoglycan (keratan sulfate and chon-
droitin sulfate) attachment regions. Proteolytic cleavage sites on the
core protein of aggrecan are displayed by black arrows. The blue
number in hexagon denotes the preferred order of cleavage
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Alteration of glycosaminoglycan metabolism in KBD
Increased catabolism of PG’s in articular cartilage is postu-
lated to cause an increase of GAG fragment release in body
fluids such as urine. Analysis of GAG excretion and their
molecular weight in urine has been used to ascertain them as
potential biomarkers for OA and RA [18, 19]. Similar mon-
itoring and analysis of GAG’s have been carried out in urine
collected from KBD patients. Previous studies have shown
that disaccharides composing CS chains, monosaccharides
including glucuronic acid and hexosamine were significantly
increased in the urine of KBD patients, whereas the molec-
ular weight of CS units in acid mucopolysaccharides were
decreased [20–22], suggesting elevated GAG catabolism in
the connective tissues from KBD patients. Moreover, there
were significantly lower sulphation patterns on disacchar-
ides analysed in urine samples from both juvenile [23] and
adult [22] KBD patients when compared with those from the
healthy, suggesting a disrupted (altered) GAG sulphation in
KBD patients. Interestingly, monkeys administrated with
water and grains from KBD areas also showed a similar
disruption of GAG metabolism (sulphation) [24, 25], sug-
gesting that environmental factors may influence GAG
metabolism.
Chondrocyte death and loss of proteoglycans in KBD
Chondrocyte death including necrosis [26] and apoptosis
[27–30] have been observed in the articular cartilage from
KBD patients. Published data indicates that PG loss from
juveniles is associated with chondronecrosis but loss and
development of degenerative cartilage changes in adult
joints may not clearly be associated with the cell death,
indicating that cell death may play different roles in PG loss
between child and adult during KBD development.
Necrosis is a form of traumatic cell death that results
from external factors such as infection, toxins, or trauma.
It is accompanied by the early loss of membrane integrity,
swelling of cytoplasm, and release of different degradative
enzymes including MMPs and ADAMTS proteinases into
the adjacent tissue [31]. Therefore, chondrocyte necrosis is
highly likely to induce the catabolism of aggrecan and
immunohistochemical analysis supports this where specific
fragments resulting from cleavage of aggrecan by
ADAMTS proteinases was localised around sites of chon-
drocyte necrosis [2].
Apoptosis is a result of a programmed cell death, which
is tightly regulated by cellular signalling events and leads to
the orderly disintegration of individual cells with shrinking
of cytoplasm, late loss of membrane integrity and no release
of degradative enzymes [32]. Therefore, it is unlikely that
cell apoptosis will induce the loss of PGs from articular
cartilage in KBD patients; this coincides with our and the
other’s observation. For example, it has been found that
chondrocyte apoptosis is elevated in the superficial and
middle zone of articular cartilage from juvenile patients
[27, 28], and is not consistent with the areas that PG deple-
tion is seen in the deep zone of articular cartilage from
juvenile patients.
However, in the analysis of articular cartilage from adult
KBD patients, apoptotic chondrocytes have been observed
in the eroded areas where PG depletion is localised [29],
indicating that there may exist some linkage between cell
apoptosis, PG degradation and progression of the disease.
Interestingly, similar observations are seen in osteoarthritic
cartilage [29, 33, 34], suggesting that the role of chondro-
cyte apoptosis in OA and KBD in mature adult cartilage
may be occurring through similar mechanistic routes. A
potential mechanism has been proposed in which apoptotic
cells in cartilage cannot be removed through phagocytosis
[35], as chondrocytes are spatially isolated in lacunae and
the abundant content of GAGs in the ECM may perturb cell
migration. Consequently, chondrocyte apoptosis may either
be diverted into secondary necrosis pathways (named
aborted apoptosis) [36, 37], or chondroapoptosis, a cell
death process involving a combination of apoptosis and
autophagy [38, 39]. This process of cell death will eventu-
ally induce focal PG degradation in the articular cartilage,
and may explain the co-localisation between apoptotic cells
and PG depletion in KBD and OA cartilage from adults.
The consequences of cell death in articular cartilage are
not only those of PG depletion but also of altered tissue
homeostasis. A decrease in chondrocyte number will com-
promise the tissues ability to repair, and this is an area
requiring further research.
Potential factors altering proteoglycan metabolism
in KBD
The precise aetiology inducing chondrocyte cell death and
altered PG metabolism in KBD patients is not clear, al-
though several factors have been proposed including sele-
nium deficiency [40], iodine deficiency [41], water pollution
with organic material and fulvic acid [42], and mycotoxin
contamination in local food [43]. Among these, selenium
deficiency and mycotoxin contamination have been exten-
sively investigated and particular attention has been given to
the biological effects they have on chondrocyte survival and
PG metabolism in articular cartilage.
The first systematic study investigating the effects of
different mycotoxins (found in KBD areas) on chondrocyte
metabolism was performed by our labs [44]. In vitro studies
using isolated chondrocytes from articular cartilage and
exposure to mycotoxins including deoxynlvalenol (DON),
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T-2 toxin, nivalenol (NIV), hutenolide (BUT), alternariol
methyl ether (AME) and monlliformin (MON) showed
increased cell DNA damage, elevated cell mortality and
altered PG metabolism. Similar findings have been
reported in animal model studies of KBD [45–48]. For
example, T-2 toxin and MON have been reported to increase
chondrocyte necrosis, reduce sGAG content and sulphation
levels in articular cartilage from animals under a selenium
deficient nutrition state [45–47]. In a recent study where rats
were administrated with T-2 toxin for up to 10 months, loss
of PG staining in articular cartilage was reported and in-
volved the entire thickness of the tibial plateaus and femoral
condyles [49].
Interestingly, selenium deficiency alone cannot induce
significant changes described above [45–47], and the alter-
ations in articular cartilage from these animal models would
be much milder if the animals were administrated with
mycotoxin under a normal selenium nutrition condition,
indicating that the supplement of selenium in the food can
alleviate the damages induced by mycotoxins [45–47, 50].
Collectively, these results suggest a combination effect of
selenium deficiency and mycotoxins on chondrocyte death
and PG catabolism.
In contrast to PGs, mycotoxins did not significantly in-
fluence collagen metabolism in articular cartilage from these
animal models, although several recent in vitro studies have
shown some mycotoxin-induced changes in type II collagen
at gene and protein levels [51–53]. This indicates that,
similar with the other degenerative joint diseases such as
OA, in KBD PGs are more vulnerable to loss and damage
than the collagen networks, although the causes of their
initial stages of degradation may be different.
The fact we must emphasize here is that there is no direct
evidence between cell death and PG depletion in the artic-
ular cartilage in these animal model studies [45–48],
because the cell death induced by mycotoxins was mainly
demonstrated by histological staining whereas the decreased
GAG content in articular cartilage was measured biochem-
ically following extraction. However, a recent rat study in
our lab has shown that the depletion of aggrecan induced by
T-2 toxin and selenium deficiency was mainly localised to
the focal areas where cell death occurred (Fig. 2), indicating
a close relationship between PG loss and chondrocyte ne-
crosis induced by mycotoxin. We also investigated chon-
drocyte apoptosis in the articular cartilage from these
experimental rats and found that it was selenium deficiency
but not T-2 toxin that significantly induced cell apoptosis;
moreover, there was no apparent correlation between the
distribution of apoptotic chondrocytes and the localisation
of aggrecan depletion (unpublished data). This suggests that
selenium deficiency induced cell apoptosis is not directly
linked to or a cause of loss of PGs from articular cartilage.
However, extensive cartilage damage was observed in ex-
perimental rats administered with mycotoxin under a low
selenium diet when compared to animals on a low selenium
diet or mycotoxin alone. This suggests that selenium defi-
ciency may be an essential “pre-challenge” for chondrocytes
before their exposure to the “fatal attack” of mycotoxins,
which eventually induces cell necrosis, and consequently
the focal PG depletion in articular cartilage.
The mechanism by which these two risk factors work
together is not clear. Previous studies have shown that
mycotoxins including T-2 toxin mainly target on cell mem-
branes by increasing oxidative stress within cells [54], sug-
gesting that the elevated reactive oxygen species may play a
pivotal role. Selenium is a key element for several antioxi-
dant selenoproteins including glutathione peroxidase (GPx)
enzymes [55]; its deficiency will dramatically reduce the
function of antioxidant systems in cells. On the basis of this
“pre-challenge”, the damage induced by mycotoxins could
Fig. 2 Aggrecan immunohistochemical staining in articular cartilage
from rat KBD animal model. KBD rat model was produced by admin-
istration with T-2 toxin and selenium deficiency food for 4 weeks. a
aggrecan positive staining evenly distributes across the whole section
of articular cartilage from control group. b Focal depletion of aggrecan
staining (hollow black arrows) was observed in the articular cartilage
from T-2 toxin and selenium deficiency group. The area enclosed with
back square was magnified and displayed in c, note the depletion of
aggrecan staining in pericellular matrix of a single chondrocyte (black
arrow), and the chondrocyte cluster formation and its strong aggrecan
staining adjacent to the focal proteoglycan loss area (hollow red ar-
row). Scale Bar: 50 μm
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be greatly aggravated, and consequently induce chondrocyte
necrosis which results in the focal PG depletion in articular
cartilage. This deduction is consistent with our recent in vivo
study [56], and may explain the synergistic effect of seleni-
um deficiency and mycotoxins described above.
Alternatively, mycotoxins could disrupt PG metabolism
directly. It has been reported that T-2 toxin significantly
inhibited aggrecan gene and protein expression in chondro-
cytes cultured in vitro [52, 57], but increased the
corresponding gene expression of degradative enzymes such
as aggrecanase-2 [57]. Moreover, mycotoxins can increase
the production of pro-inflammatory cytokines such as IL-1β
and TNF-α in vitro [58, 59] and in vivo [60], similar to their
elevated levels reported in KBD patients [2, 14, 16, 17, 61,
62]. These increased levels of pro-inflammatory cytokines
could undoubtedly promote the catabolism of PGs in the
ECM of articular cartilage. This may explain the significant
inhibition of PG synthesis in chondrocytes cultured with
serum from KBD patients [63, 64], where elevated TNFα
and IL-1β levels were detected.
Mycotoxins may also interfere with GAG metabolism
and subsequently influence PG maintenance and function
in articular cartilage. Recently, in our lab an immunohisto-
chemical study using CS/DSmotif antibodies has been carried
out on articular cartilage taken from rats administered a low
selenium diet and/or T2 toxin. This study indicates that there
is altered expression of CS/DS GAG chains under the differ-
ent experimental conditions (Fig. 3), providing evidence
that altered GAG synthesis maybe involved in the patho-
genesis of KBD.
Proteoglycan metabolism, chondrocyte death
and biomechanical consequences
One unique pathological change in the articular cartilage
from KBD patients is the “focal” cell death and its associ-
ated “localised” loss of PGs in the ECM. Similar changes
have also been observed in different KBD animal models
[45–48, 65, 66] including mycotoxins and selenium defi-
ciency induced pig, rat and chicken models. However, it is
not clear why this characteristic change is restricted to
regional areas of the articular cartilage, although it is most
likely related to the different biomechanical distribution
across the articular cartilage. Unfortunately, related biome-
chanical studies have not been performed, especially in the
articular cartilage from either KBD patients or animal mod-
els. Therefore, the following discussion is largely based
upon the knowledge obtained from studies of other degen-
erative joint diseases such as OA.
Fig. 3 Immunostaining for chondroitin sulphate (CS)/dermatan sul-
phate (DS) expression in articular cartilage from KBD animal model.
KBD rat model was produced by administration with T-2 toxin and
selenium deficiency food for 4 weeks. The expression of different
epitopes (6C3 and 7D4) along CS/DS chains on proteoglycans in
articular cartilage was investigated using immunohistochemical stain-
ing (red colour). 6C3 and 7D4 positive staining is mainly localised in
the pericellular matrix. In the articular cartilage from control group,
6C3 and 7D4 positive staining is observed in all layers, although the
most of the intensive staining is in the superficial and middle zone. In
contrast, there is no or very weak 6C3 and 7D4 positive staining in
middle and deep zones of articular cartilage from low selenium diet
plus T-2 toxin (KBD model group). Interestingly, much stronger pos-
itive staining of 6C3 and 7D4 epitopes is observed in the superficial
zone of articular cartilage from KBD model group. These results
indicate the alteration of CS/DS metabolism induced by selenium
deficiency nutrition and T-2 toxin. Scale Bar: 50 μm
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There is a distinct compressive loading (from 1 MPa to
25 MPa) applied to the articular cartilage in major joints
such as the knee [67], which will greatly influence chon-
drocyte metabolism and PG turnover [68]. In healthy artic-
ular cartilage, physiological compressive stimulation
usually increases the synthesis of PGs to help resist the
mechanical loading, which is negatively regulated by nitric
oxide (NO)-dependent signalling pathways [68, 69].
However, under pathological conditions such as KBD, the
elevated oxidative stress [56] and high levels of NO [28] in
articular cartilage could severely interfere with the biome-
chanotransduction signalling cascades and subsequently in-
hibit PG synthesis in chondrocytes in response to loading
[70]. Therefore, chondrocytes may not maintain normal PG
production in response to mechanical loading, which could
greatly change the mechanical properties of the pericellular
matrix; this change could subsequently induce abnormally
higher mechanical load applied on cells, further interfering
with chondrocyte metabolism. At the end of this process,
chondrocytes cannot maintain their microenvironment and
thereby cell death is induced. Alternatively, compressive
loading could directly induce chondrocyte death but mainly
at high strain rate (non-physiological) as reported previously
[71, 72]. However, in KBD patients, the threshold of chon-
drocyte mortality in response to compressive loading is
greatly decreased [73] under pathological conditions such
as high oxidative stress. Therefore, cell necrosis and subse-
quent focal PG depletion could happen in the areas of
articular cartilage resisting higher (but still physiological)
compressive loading. Collectively, these two possibilities
may explain the focal cell death and PG depletion in the
articular cartilage from both KBD patients and animal mod-
els. Of course, biomechanical studies are needed in future
studies.
Therapeutic targets of KBD
Currently, there are no specific treatment methods for KBD
patients available due to the unknown aetiologies of this
disease. However, based on the selenium deficiency and my-
cotoxin contamination hypotheses, a series of measures have
been performed in KBD endemic areas including provision of
the susceptible population (especially children) with dietary
grain imported from non-KBD areas and selenium supple-
ments [74], which have greatly decreased the prevalence of
KBD [75, 76]. Due to the similar pathological changes be-
tween OA and adult KBD patients, several treatments used for
OA patients including GAG supplement [77, 78], hyaluronic
acid injection into joint space [79] have been tested on KBD
patients and these have shown some benefits. Considering the
high levels of TNF and IL-1 in synovial fluid from KBD
patients and the pivotal role these cytokines play in PG
degradation, another potential therapeutic target for KBD are
the anti-inflammatory cytokines. Unfortunately, the related
clinical trials on KBD patients are still ongoing.
Conclusion
Although KBD has been known and studied for many years,
the precise pathological mechanism of the disease is still
poorly understood. It is now believed that KBD is not
caused by a single risk factor but by multi-risk factors.
The disease is characterised by pathological changes in the
articular cartilage by focal chondrocyte death (necrosis) and
an associated PG depletion. This may be derived from the
risk factor-induced disruption of PG metabolism and subse-
quent abnormal biomechanical strain distribution applied on
chondrocytes. In this mini-review, we propose mechanisms
to explain how chronic matrix remodelling processes and
cell death contribute to structural damage that characterizes
KBD. More research is required to fully characterize the
detail mechanism of KBD.
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